WO1993019769A1 - Wound healing and treatment of fibrotic disorders - Google Patents

Wound healing and treatment of fibrotic disorders Download PDF

Info

Publication number
WO1993019769A1
WO1993019769A1 PCT/GB1993/000586 GB9300586W WO9319769A1 WO 1993019769 A1 WO1993019769 A1 WO 1993019769A1 GB 9300586 W GB9300586 W GB 9300586W WO 9319769 A1 WO9319769 A1 WO 9319769A1
Authority
WO
WIPO (PCT)
Prior art keywords
tgfβ
fibrotic
composition according
growth factor
binding
Prior art date
Application number
PCT/GB1993/000586
Other languages
French (fr)
Inventor
Mark William James Ferguson
Mamta Shah
Original Assignee
The Victoria University Of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002131383A priority Critical patent/CA2131383C/en
Priority to AU37623/93A priority patent/AU673161B2/en
Priority to JP51719393A priority patent/JP3919212B2/en
Priority to DE69332624T priority patent/DE69332624T2/en
Priority to BR9306226A priority patent/BR9306226A/en
Priority to US08/307,640 priority patent/US6331298B1/en
Application filed by The Victoria University Of Manchester filed Critical The Victoria University Of Manchester
Priority to DK93906723T priority patent/DK0646012T3/en
Priority to EP93906723A priority patent/EP0646012B1/en
Priority to AT93906723T priority patent/ATE230605T1/en
Priority to SK1168-94A priority patent/SK116894A3/en
Publication of WO1993019769A1 publication Critical patent/WO1993019769A1/en
Priority to NO943466A priority patent/NO943466L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention concerns the healing of wounds and other conditions in which fibrosis is a major mechanism of tissue repair or where excessive fibrosis leads to pathological derangement and malfunctioning of the tissues. It refers in particular to agents and techniques for facilitating repair and healing of animal tissues, without excessive fibrosis, and for preventing or treating diseases and conditions of fibrosis.
  • Fibrosis is a major problem in wound healing causing scarring of the tissue, which not only looks unsightly, but also causes problems in respect of growth of the tissue, function, movement etc. This is particularly true following injuries to children or following major burns.
  • fibrosis is a major medical problem where abnormal or excessive deposition of fibrous tissue occurs in many diseases, including liver cirrhosis, glomerulonephritis, pulmonary fibrosis, systemic fibrosis, rheumatoid arthritis, as well ' as wound healing,
  • cytokines are responsible for the proliferation of fibroblasts and the deposition of extracellular matrix proteins (including collagen and fibronectin) which accumulate and result in permanent alteration in tissue structure and function.
  • TGF tumor necrosis factor
  • FGF's fibroblast growth factors
  • PDGF platelet derived growth factor
  • TGF ⁇ transforming growth factor ⁇
  • TGF ⁇ -1 to TGF ⁇ -5 have so far been identifeid
  • TGF ⁇ and PDGF Two of these cytokine families, TGF ⁇ and PDGF, have been reported to be highly fibrogenic, and, moreover, inhibition of two of the TGFB's and PDGF activity, using anti-TGF ⁇ -1, anti-TGF ⁇ -2 and anti-PDGF antibodies, has been shown to diminish fibrosis in tissue injury (Shah el al, The Lancet, 339, 213-214, 1992; WO 91/04748).
  • the present invention provides novel compositions useful in the treatment of wounds and fibrotic disorders and which may prevent, inhibit or reverse fibrosis.
  • the invention comprises a healing composition containing at least one non-fibrotic growth factor in combination with a pharmaceutically acceptable carrier.
  • the composition may comprise TGF ⁇ -3 as the or a non-fibrotic growth factor, such that on application of the composition to the tissue, this non-fibrotic growth factor is present in an elevated level compared to its naturally occuring level.
  • composition may comprise acidic or basic FGF as the or a non-fibrotic growth factor, again resulting in a much elevated level of non-fibrotic growth factor than would naturally be present.
  • the composition may comprise anti-fibrotic agents, such as fibrotic growth factor neutralising agents, for example antibodies to TGFfl-1, TGF ⁇ -2 and PDGF; binding proteins which prevent TGF ⁇ -1, TGF ⁇ -2 and PDGF from binding to their receptors by either binding to the growth factor itself, eg. Decorin, Biglycan, or binding to the receptor, eg. peptides containing the receptor binding site sequence or soluble forms of the growth factor receptors and the growth factor binding domains of these receptors; and antisense oligo- nucleotides or ribosymes which act to prevent fibrotic growth factor RNA translation.
  • anti-fibrotic agents such as fibrotic growth factor neutralising agents, for example antibodies to TGFfl-1, TGF ⁇ -2 and PDGF
  • binding proteins which prevent TGF ⁇ -1, TGF ⁇ -2 and PDGF from binding to their receptors by either binding to the growth factor itself, eg. Decorin, Biglycan, or binding to the receptor, eg. peptides
  • composition may comprise combinations of non-fibrotic growth factors, for example, TGF ⁇ -3 and anti-fibrotic agents, for example, anti-TGF ⁇ -1 and anti- TGF ⁇ -2.
  • non-fibrotic growth factors for example, TGF ⁇ -3
  • anti-fibrotic agents for example, anti-TGF ⁇ -1 and anti- TGF ⁇ -2.
  • the non-fibrotic growth factor and/or anti-fibrotic agent(s) may be present in the composition in an active or inactive form. Inactivation may be by _-_.-
  • Capsules may be degradeable by an external stimulus to release the active form when required.
  • the external stimulus may include UV light, ultrasound, in vivo enzymes or heat.
  • Inactivation may, however, be by the molecular addition of a binding molecule.
  • the binding molecule may be detachable when required by an external stimulus such as UV light, ultrasound, in vivo enzymes or heat.
  • the non-fibrotic growth factor may be present in an inactive form, for example, as a precursor, and may be activated upon contact with tissue containing the natural cleavage enzymes required to convert the precursor into its active form.
  • the carrier may comprise a neutral sterile cream, gel, aerosol or powder for topical application, or may be in the form of a patch, sterile dressing or an absorbable dressing.
  • the carrier may be a biopolymer of collagen, hyaluronic acid or polymer of PVC to which the anti-fibrotic or non fibrotic agents are attached in such a way as to facilitate their action and/or release when the carrier is in contact with or implanted into either the wound or fibrotic lesion.
  • the carrier may also comprise a sterile solution for irrigation, injection either locally or systemically or inhalation, or may be in the form of a tablet, capsule, and the like, for enteral administration.
  • the present invention also provides a method of preparation of a pharmaceutical healing or anti-fibrotic composition containing at least one non-fibrotic growth factor for topical application in a cream, gel, aerosol, powder, patch, dressing, biopolymer or polymer implant, delay or slow release system, or in a solution for irrigation, injection or inhalation, or in a tablet or capsule for enteral administration.
  • the present invention also provides a method of inhibiting fibrosis during the healing of wounds and in other fibrotic conditions and disorders , for example ulcers, comprising administering to a host suffering from tissue wounding or other fibrotic conditions and disorders, at least one non-fibrotic growth factor.
  • the present invention also provides a method * of reversing fibrosis in such fibrotic conditions and disorders comprising administering to a host suffering from such fibrotic conditions and disorders, at least one non-fibrotic growth factor, for example, TGF ⁇ -3 and/or at least one anti-fibrotic agent for example, anti-TGF ⁇ -l/TGF ⁇ -2.
  • at least one non-fibrotic growth factor for example, TGF ⁇ -3
  • at least one anti-fibrotic agent for example, anti-TGF ⁇ -l/TGF ⁇ -2.
  • TGF ⁇ two cytokines have been identified as being involved in fibrosis, namely PDGF and TGF ⁇ . Of these two, TGF ⁇ appears to play the major role. For example, in tissues which heal without scar formation, such as fetal and embryonic wounds where there is a lowered inflammatory response and altered cytokine profile, the level of TGF ⁇ in particular, is much reduced.
  • TGF ⁇ comprises a family of molecules, the important mammalian members being TGF ⁇ -1, TGF ⁇ -2 and TGF ⁇ -3 (Roberts and Sporn, The Transforming Growth Factor- ⁇ s, In: Peptide Growth Factors and their Receptors, Springer Verlag, Berlin, 1990, p418-472).
  • the TGF ⁇ s although having different patterns ,of expression, share over 70% peptide homology and are thought to have similar functions and act inter ⁇ changeably. Thus in wound healing it would be expected that TGF ⁇ -3 would act like TGF ⁇ -1 and TGF ⁇ -2 to increase extracellular matrix production, angiogenesis and the inflammatory response.
  • fibrotic disease is a major medical problem.
  • diseases there is abnormal or excessive deposition of fibrous tissue.
  • Such diseases are exemplified by liver cirrhosis, glomerulonephritis, pulmonary fibrosis, systemic fibrosis and rheumatoid arthritis.
  • TGF ⁇ would be avoided, since TGF ⁇ 's are believed to increase the deposition of fibrous tissue.
  • TGF ⁇ -3 has the opposite effect to that expected, in that it promotes healing without promoting the deposition of fibrous tissue.
  • the present invention provides the use of a TGF ⁇ -3 for the manufacture of a medicament for the treatment of a fibrotic disease.
  • the present invention also provides a method of treating a fibrotic disease by administering a pharmaceutically effective amount of TGF ⁇ -3 to a patient in need thereof.
  • the present invention also provides an agent for treating a fibrotic disease which comprises TGF ⁇ -3 as active ingredient.
  • the present invention also provides a pharmaceutical composition comprising a higher proportion of TGF ⁇ -3 in relation to TGF ⁇ -1 or TGF ⁇ -2, compared with relative proportions in naturally occuring TGF ⁇ , and a ' pharmaceutically acceptable carrier.
  • EP 0 433 225 defines the biological activity of the TGF ⁇ 's ie. TGF ⁇ -1, TGF ⁇ -2 and TGF ⁇ -3, as including the ability to increase formation of fibrous granular tissue in and around wound implants in rats (page 5, lines 17-19), while US 4,810,691 and US 4,774,228 describe the use of TGF ⁇ 's for promoting connective tissue deposition.
  • TGF ⁇ -3 acts in the same manner as TGF ⁇ -1 and TGF ⁇ -2 to increase fibrosis at the site of wound healing, it has in fact the opposite effect and promotes wound healing with reduced fibrosis and scarring.
  • TGF ⁇ -1 TGF ⁇ -2 or TGF ⁇ -3. They have also involved the injection of neutralising antibodies to TGF ⁇ -1 or TGF ⁇ -2 (or anti TGF ⁇ -1 and TGF ⁇ -2 in combination) . Neutralising antibodies to TGF ⁇ -3 are not yet available.
  • the experimental protocol was as described in Shah et al, The Lancet, 339 - 213-214, 1992)
  • the neutralising antibody to TGF ⁇ -1 diminished scarring, i.e. reduced the amount of extracellular matrix, reduced angiogenesis and reduced the numbers of macrophages and monocytes at the wound. It also improved the orientation of collagen fibres in the healing wound.
  • the neutralising antibody to TGF ⁇ -2 had very little effect on its own, but showed a slight improvement in scarring.
  • the neutralising antibodies to TGF ⁇ -1 and TGF ⁇ -2 showed a marked improvement in wound healing (similar to that described in Shah et al, The Lancet, 339 , 213-214, 1992), namely decreased extracellular matrix deposition (decreased fibronectin, decreased collagen), decreased angiogenesis, decreased macrophages and monocytes at the wound site and better orientation of collagen and fibronectin within the wound.
  • Exogenous addition of TGF ⁇ -1 or TGF ⁇ -2 had the expected result, namely of increasing extracellular matrix deposition and angiogenesis.
  • TGF ⁇ -3 did not have this effect, but rather produced effects similar to those observed with the neutralising antibodies to TGF ⁇ -1 and TGF ⁇ -2, namely, a reduction in the amount of extracellular matrix deposited, a decrease in macrophages and monocytes and a marked improvement in subsequent scarring.
  • Specific details of the experiments to document the TGF ⁇ -3 effect are as follows :-
  • TGF ⁇ -1 transforming growth factor beta 1
  • TGF ⁇ -2 20 ng per injection
  • TGF ⁇ -3 20 ng per injection
  • the wounds were processed for routine histological examination, particularly using connective tissue stains such as Mallory or Masson's trichrome. They were also processed for immuno- cytochemistry, using antibodies to detect fibronectin (as a marker of early wound repair and to show the orientation of extracellular matrix molecules) , macrophages and monocytes (as an indication of the inflammatory response), laminin (to highlight basement membranes, e.g. of newly formed blood vessels) and collagen types I and III to document connective tissue deposition within the wound and scarring.
  • connective tissue stains such as Mallory or Masson's trichrome. They were also processed for immuno- cytochemistry, using antibodies to detect fibronectin (as a marker of early wound repair and to show the orientation of extracellular matrix molecules) , macrophages and monocytes (as an indication of the inflammatory response), laminin (to highlight basement membranes, e.g. of newly formed blood vessels) and collagen types I and III to document connective tissue deposition within
  • the TGF ⁇ -3 treated wounds had less fibronectin and the fibronectin fibres were in a beter orientation.
  • the fibronectin in all wounds was similar in quantity to that of the surrounding normal skin.
  • that in the TGF ⁇ -3 treated wound had a much better orientation than the other wounds.
  • the results were almost indistinguishable from the results obtained with neutralising antibodies to TGF ⁇ -1 and TGF ⁇ -2.
  • wounds treated with TGF ⁇ -1 or TGF ⁇ -2 showed a vastly increased quantity of fibronectin in the wound at 7 days and this fibronectin had an abnormal orientation, compared to the surrounding tissue. The same was true at 14 days, but by 6 weeks there was little difference between the TGF ⁇ -1 or TGF ⁇ -2 treated wounds and the control in terms of the quantity of fibronectin present.
  • TGF ⁇ -1 treated and TGF ⁇ -2 treated and control wounds showed similar profiles of macrophage and monocyte infiltration (for example control 159, TGF ⁇ -1 149, control 117, TGF ⁇ -2 112 per section).
  • TGF ⁇ -3 treated wounds had a low profile of macrophage plus monocyte infiltration (control 130, TGF ⁇ -3 91 per section) .
  • TGF ⁇ -1 treated and TGF ⁇ -2 treated wounds had a higher profile of macrophages in the lower half of the wounds compared to similar areas in the control wounds (control 50/TGF ⁇ -l 80, control 45/ TGF ⁇ -2 59 per section) .
  • control 50/TGF ⁇ -l 80, control 45/ TGF ⁇ -2 59 per section the macrophage infiltration was similar in the TGF ⁇ -1 treated and control wounds (control 37, TGF ⁇ -1 39 per section) whilst TGF ⁇ -2 treated wounds had a lower profile (control 34, TGF ⁇ -2 19).
  • TGF ⁇ -3 treated wounds showed a lower macrophage profile throughout the entire wound, compared to the control wounds (upper half control 41, TGF ⁇ -3 16; lower half control 72, TGF ⁇ -3 28 per section).
  • TGF ⁇ -1 treated wounds showed an increase in the number of blood vessels, particularly at the base of the wound.
  • TGF ⁇ -2 treated wounds appeared similar to the control wounds.
  • TGF ⁇ -3 treated wounds had many more blood vessels compared to either the control or the TGF ⁇ -1 or the TGF ⁇ -2 treated wounds. This was a very marked effect.
  • TGF ⁇ -1, TGF ⁇ -2 or TGF ⁇ -3 treated wounds By 14 days there were few differences in the number of blood vessels between either the TGF ⁇ -1, TGF ⁇ -2 or TGF ⁇ -3 treated wounds compared to the control. However, the TGF ⁇ -3 treated wounds tended to have more blood vessels.
  • TGF ⁇ -3 treated wounds had a more similar dermal architecture to that of the surrounding normal skin, compared to either the control TGF ⁇ -1 or TGF ⁇ -2 treated wounds. .
  • This result with TGF ⁇ -3 is very similar to that obtained with neutralising antibodies to TGF ⁇ -1 and TGF ⁇ -2.
  • treatment of the wounds with TGFfi-3 decreased the amount of extracellular matrix deposited in the early wound, assured that the orientation of this matrix was in the normal reticular pattern of the dermis, compared to the abnormal pattern of the scar, decreased the number of macrophages and monocytes and hence inflammatory infiltrate into the wound, but greatly increased the number of blood vessels in the early healing wound.
  • Treatment of the wounds with neutralising antibodies to TGF ⁇ -1 and TGF ⁇ -2 decrease the amount of extracellular matrix deposited, alter the orientation of this matrix, so that it is in a more normal alignment, decrease the inflammatory infiltrate of macrophages and monocytes (like TGF ⁇ -3) but decrease the number of blood vessels (unlike treatment with TGF ⁇ -3 which increases the number of blood vessels).
  • TGF ⁇ -3 therefore acts as an anti-scarring (anti-fibrotic) agent. It is very clear that this is an isoform specific effect within the TGF ⁇ family.
  • TGF ⁇ -3 therefore becomes a target as an anti-fibrotic agent or an anti-scarring agent. It may be capable of biological modification to increase the anti-fibrotic effect or define more carefully that portion of the molecule responsible for these effects. It may be possible to optimise the structure of TGF ⁇ -3 as an anti-fibrotic agent, based on such analysis.
  • the effects of TGF ⁇ -3 in this regard are unpredictable from the literature, and interestingly, differ from the neutralising antibody experiments, particularly in the increase in angiogenesis. This may actually be beneficial for certain kinds of wound healing, e.g. chronic wounds such as venous leg ulcers, where one wants to increase the vascular supply to stimulate healing but decrease subsequent scarring.
  • TGF ⁇ -3 or anti TGF ⁇ -1/TGF ⁇ -2 agents are not limited to preventing further increases of fibrosis.
  • TGF ⁇ -l/TGF ⁇ -2 act to increase the accumulation of extracellular matrix molecules both by stimulating synthesis of new extracellular matrix molecules and decreasing the removal of existing matrix molecules, i.e. inhibiting tissue turnover (Roberts and Sporn, the transforming growth factor - ⁇ 's, In: Peptide growth factors and their receptors, Springer Verlag, Berlin, 1990, p 418-472) . Therefore, any agent which antagonises or neutralises or renders ineffective TGF ⁇ -1/TGF ⁇ -2 not only decreases extracellular matrix synthesis but also increases remodelling.
  • TGF ⁇ -3 or anti-TGF ⁇ -1/anti- TGF ⁇ -2/anti-PDGF may in certain fibrotic diseases, e.g. glomerulonephritis, pulmonary fibrosis, reverse the accumulation of fibrous scar tissue already present in the tissue.
  • fibrotic growth factor neutralising agen for example, anti-TGF ⁇ -1 and/or anti-TGF ⁇ -2 and/or anti-PDGF antibodies, in a ratio which will enable the required amount of vascularisation for the particular type of wound to be provided whilst at the same time healing the wound without scarring.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A healing composition containing at least one non-fibrotic growth factor in combination with a pharmaceutically acceptable carrier is disclosed. A method of preparation of the composition and method of treating a host, suffering from a wound or fibrotic condition, disease, disorder with the composition is also disclosed.

Description

WOUNDHEALINGANDTREATMENTOFF.BROTIC DISORDERS
This invention concerns the healing of wounds and other conditions in which fibrosis is a major mechanism of tissue repair or where excessive fibrosis leads to pathological derangement and malfunctioning of the tissues. It refers in particular to agents and techniques for facilitating repair and healing of animal tissues, without excessive fibrosis, and for preventing or treating diseases and conditions of fibrosis.
Fibrosis is a major problem in wound healing causing scarring of the tissue, which not only looks unsightly, but also causes problems in respect of growth of the tissue, function, movement etc. This is particularly true following injuries to children or following major burns.
In addition, fibrosis is a major medical problem where abnormal or excessive deposition of fibrous tissue occurs in many diseases, including liver cirrhosis, glomerulonephritis, pulmonary fibrosis, systemic fibrosis, rheumatoid arthritis, as well 'as wound healing,
The mechanism of fibrosis is still not fully understood, but wound healing usually begins as an inflammatory reaction with leucocyte infiltration and accumulation of cyto ines. These cytokines are responsible for the proliferation of fibroblasts and the deposition of extracellular matrix proteins (including collagen and fibronectin) which accumulate and result in permanent alteration in tissue structure and function.
Examples of the regulatory cytokines include tumor necrosis factor (TNF), fibroblast growth factors (FGF's), platelet derived growth factor (PDGF) and transforming growth factor β (TGFβ), (TGFβ-1 to TGFβ-5 have so far been identifeid) . Two of these cytokine families, TGFβ and PDGF, have been reported to be highly fibrogenic, and, moreover, inhibition of two of the TGFB's and PDGF activity, using anti-TGFβ-1, anti-TGFβ-2 and anti-PDGF antibodies, has been shown to diminish fibrosis in tissue injury (Shah el al, The Lancet, 339, 213-214, 1992; WO 91/04748).
The present invention provides novel compositions useful in the treatment of wounds and fibrotic disorders and which may prevent, inhibit or reverse fibrosis.
The invention comprises a healing composition containing at least one non-fibrotic growth factor in combination with a pharmaceutically acceptable carrier. The composition may comprise TGFβ-3 as the or a non-fibrotic growth factor, such that on application of the composition to the tissue, this non-fibrotic growth factor is present in an elevated level compared to its naturally occuring level.
The composition may comprise acidic or basic FGF as the or a non-fibrotic growth factor, again resulting in a much elevated level of non-fibrotic growth factor than would naturally be present.
The composition may comprise anti-fibrotic agents, such as fibrotic growth factor neutralising agents, for example antibodies to TGFfl-1, TGFβ-2 and PDGF; binding proteins which prevent TGFβ-1, TGFβ-2 and PDGF from binding to their receptors by either binding to the growth factor itself, eg. Decorin, Biglycan, or binding to the receptor, eg. peptides containing the receptor binding site sequence or soluble forms of the growth factor receptors and the growth factor binding domains of these receptors; and antisense oligo- nucleotides or ribosymes which act to prevent fibrotic growth factor RNA translation.
The composition may comprise combinations of non-fibrotic growth factors, for example, TGFβ-3 and anti-fibrotic agents, for example, anti-TGFβ-1 and anti- TGFβ-2.
The non-fibrotic growth factor and/or anti-fibrotic agent(s) may be present in the composition in an active or inactive form. Inactivation may be by _-_.-
any of a number of mechanisms, for example, by encapsulation. Capsules may be degradeable by an external stimulus to release the active form when required. The external stimulus may include UV light, ultrasound, in vivo enzymes or heat.
Inactivation may, however, be by the molecular addition of a binding molecule. The binding molecule may be detachable when required by an external stimulus such as UV light, ultrasound, in vivo enzymes or heat.
The non-fibrotic growth factor may be present in an inactive form, for example, as a precursor, and may be activated upon contact with tissue containing the natural cleavage enzymes required to convert the precursor into its active form.
The carrier may comprise a neutral sterile cream, gel, aerosol or powder for topical application, or may be in the form of a patch, sterile dressing or an absorbable dressing. The carrier may be a biopolymer of collagen, hyaluronic acid or polymer of PVC to which the anti-fibrotic or non fibrotic agents are attached in such a way as to facilitate their action and/or release when the carrier is in contact with or implanted into either the wound or fibrotic lesion. The carrier may also comprise a sterile solution for irrigation, injection either locally or systemically or inhalation, or may be in the form of a tablet, capsule, and the like, for enteral administration.
The present invention also provides a method of preparation of a pharmaceutical healing or anti-fibrotic composition containing at least one non-fibrotic growth factor for topical application in a cream, gel, aerosol, powder, patch, dressing, biopolymer or polymer implant, delay or slow release system, or in a solution for irrigation, injection or inhalation, or in a tablet or capsule for enteral administration.
The present invention also provides a method of inhibiting fibrosis during the healing of wounds and in other fibrotic conditions and disorders , for example ulcers, comprising administering to a host suffering from tissue wounding or other fibrotic conditions and disorders, at least one non-fibrotic growth factor.
The present invention also provides a method*of reversing fibrosis in such fibrotic conditions and disorders comprising administering to a host suffering from such fibrotic conditions and disorders, at least one non-fibrotic growth factor, for example, TGFβ-3 and/or at least one anti-fibrotic agent for example, anti-TGFβ-l/TGFβ-2. As mentioned above, two cytokines have been identified as being involved in fibrosis, namely PDGF and TGFβ. Of these two, TGFβ appears to play the major role. For example, in tissues which heal without scar formation, such as fetal and embryonic wounds where there is a lowered inflammatory response and altered cytokine profile, the level of TGFβ in particular, is much reduced.
TGFβ comprises a family of molecules, the important mammalian members being TGFβ-1, TGFβ-2 and TGFβ-3 (Roberts and Sporn, The Transforming Growth Factor-βs, In: Peptide Growth Factors and their Receptors, Springer Verlag, Berlin, 1990, p418-472). The TGFβs, although having different patterns ,of expression, share over 70% peptide homology and are thought to have similar functions and act inter¬ changeably. Thus in wound healing it would be expected that TGFβ-3 would act like TGFβ-1 and TGFβ-2 to increase extracellular matrix production, angiogenesis and the inflammatory response.
As discussed above, fibrotic disease is a major medical problem. In such diseases, there is abnormal or excessive deposition of fibrous tissue. Such diseases are exemplified by liver cirrhosis, glomerulonephritis, pulmonary fibrosis, systemic fibrosis and rheumatoid arthritis. In such diseases the use of TGFβ would be avoided, since TGFβ's are believed to increase the deposition of fibrous tissue. Suprisingly, it has now been discovered that TGFβ-3 has the opposite effect to that expected, in that it promotes healing without promoting the deposition of fibrous tissue.
The present invention provides the use of a TGFβ-3 for the manufacture of a medicament for the treatment of a fibrotic disease.
The present invention also provides a method of treating a fibrotic disease by administering a pharmaceutically effective amount of TGFβ-3 to a patient in need thereof.
The present invention also provides an agent for treating a fibrotic disease which comprises TGFβ-3 as active ingredient.
The present invention also provides a pharmaceutical composition comprising a higher proportion of TGFβ-3 in relation to TGFβ-1 or TGFβ-2, compared with relative proportions in naturally occuring TGFβ, and a' pharmaceutically acceptable carrier. EP 0 433 225 defines the biological activity of the TGFβ's ie. TGFβ-1, TGFβ-2 and TGFβ-3, as including the ability to increase formation of fibrous granular tissue in and around wound implants in rats (page 5, lines 17-19), while US 4,810,691 and US 4,774,228 describe the use of TGFβ's for promoting connective tissue deposition.
Experiments described in detail below indicate that contrary to the conventional view that TGFβ-3 acts in the same manner as TGFβ-1 and TGFβ-2 to increase fibrosis at the site of wound healing, it has in fact the opposite effect and promotes wound healing with reduced fibrosis and scarring.
Experiments
The experiments have involved exogenous injection of TGFβ-1, TGFβ-2 or TGFβ-3. They have also involved the injection of neutralising antibodies to TGFβ-1 or TGFβ-2 (or anti TGFβ-1 and TGFβ-2 in combination) . Neutralising antibodies to TGFβ-3 are not yet available. The experimental protocol was as described in Shah et al, The Lancet, 339 - 213-214, 1992)
These experiments produced a very interesting and unexpected set of results. First, the neutralising antibody to TGFβ-1 diminished scarring, i.e. reduced the amount of extracellular matrix, reduced angiogenesis and reduced the numbers of macrophages and monocytes at the wound. It also improved the orientation of collagen fibres in the healing wound. The neutralising antibody to TGFβ-2 had very little effect on its own, but showed a slight improvement in scarring. Combined, the neutralising antibodies to TGFβ-1 and TGFβ-2 showed a marked improvement in wound healing (similar to that described in Shah et al, The Lancet, 339 , 213-214, 1992), namely decreased extracellular matrix deposition (decreased fibronectin, decreased collagen), decreased angiogenesis, decreased macrophages and monocytes at the wound site and better orientation of collagen and fibronectin within the wound. Exogenous addition of TGFβ-1 or TGFβ-2 had the expected result, namely of increasing extracellular matrix deposition and angiogenesis. However, exogenous addition of TGFβ-3 did not have this effect, but rather produced effects similar to those observed with the neutralising antibodies to TGFβ-1 and TGFβ-2, namely, a reduction in the amount of extracellular matrix deposited, a decrease in macrophages and monocytes and a marked improvement in subsequent scarring. Specific details of the experiments to document the TGFβ-3 effect are as follows :-
Adult male Sprague-Dawley rats (200 to 250 gram weight) were anaesthetised with halothane nitrous oxide and oxygen inhalation. Two incisions, ten millimetres in length and to the depth of the parniculous carnosis were made in the dorsal skin, equal distant from the midline and between the fore and hind limbs. The wounds were left unsutured to heal by secondary intention to produce the greatest amount of granulation tissue and scarring. In each animal, one wound (control) was unmanipulated. In different animals the other wound received a) an injection of transforming growth factor beta 1 (TGFβ-1) (20 ng per injection), or b) an injection of TGFβ-2 (20 ng per injection) or c) an injection of TGFβ-3 (20 ng per injection). It had previously been determined from dose response experiments that 20 ng per injection was the optimum dose to give. Injections were of 100 microlitres in phosphate buffered saline and were introduced into the wound margins by local infiltration on days 0, 1 and 2. The fluid was infiltrated along the length of each wound margin through a single entry point 0.5 cm distal to the caudal end of the wound. At least four animals were killed by chloroform overdose on each of days 7, 14 and 42 after wounding. The wounds were processed for routine histological examination, particularly using connective tissue stains such as Mallory or Masson's trichrome. They were also processed for immuno- cytochemistry, using antibodies to detect fibronectin (as a marker of early wound repair and to show the orientation of extracellular matrix molecules) , macrophages and monocytes (as an indication of the inflammatory response), laminin (to highlight basement membranes, e.g. of newly formed blood vessels) and collagen types I and III to document connective tissue deposition within the wound and scarring.
Summary of Results
Compared to control wounds, at 7 and 14 days, the TGFβ-3 treated wounds had less fibronectin and the fibronectin fibres were in a beter orientation. By six weeks, the fibronectin in all wounds was similar in quantity to that of the surrounding normal skin. However, that in the TGFβ-3 treated wound had a much better orientation than the other wounds. The results were almost indistinguishable from the results obtained with neutralising antibodies to TGFβ-1 and TGFβ-2. By comparison, wounds treated with TGFβ-1 or TGFβ-2 showed a vastly increased quantity of fibronectin in the wound at 7 days and this fibronectin had an abnormal orientation, compared to the surrounding tissue. The same was true at 14 days, but by 6 weeks there was little difference between the TGFβ-1 or TGFβ-2 treated wounds and the control in terms of the quantity of fibronectin present.
At 7 days TGFβ-1 treated and TGFβ-2 treated and control wounds showed similar profiles of macrophage and monocyte infiltration (for example control 159, TGFβ-1 149, control 117, TGFβ-2 112 per section). However, TGFβ-3 treated wounds had a low profile of macrophage plus monocyte infiltration (control 130, TGFβ-3 91 per section) .
At 7 days TGFβ-1 treated and TGFβ-2 treated wounds had a higher profile of macrophages in the lower half of the wounds compared to similar areas in the control wounds (control 50/TGFβ-l 80, control 45/ TGFβ-2 59 per section) . However, in the upper half of the wounds the macrophage infiltration was similar in the TGFβ-1 treated and control wounds (control 37, TGFβ-1 39 per section) whilst TGFβ-2 treated wounds had a lower profile (control 34, TGFβ-2 19). By contrast, TGFβ-3 treated wounds showed a lower macrophage profile throughout the entire wound, compared to the control wounds (upper half control 41, TGFβ-3 16; lower half control 72, TGFβ-3 28 per section). Laminin staining was used as a marker of neovascularisation. At 7 days, TGFβ-1 treated wounds showed an increase in the number of blood vessels, particularly at the base of the wound. TGFβ-2 treated wounds appeared similar to the control wounds. TGFβ-3 treated wounds, however, had many more blood vessels compared to either the control or the TGFβ-1 or the TGFβ-2 treated wounds. This was a very marked effect.
By 14 days there were few differences in the number of blood vessels between either the TGFβ-1, TGFβ-2 or TGFβ-3 treated wounds compared to the control. However, the TGFβ-3 treated wounds tended to have more blood vessels.
In terms of collagen deposition within the wound, as assayed by allory staining or im unocyto- chemistry, treatment of the wound with either TGFβ-1 or TGFβ-2 increased the amount of collagen within the wound on days 7 and 14 after wounding. Furthermore, this collagen had an abnormal orientation with a'much higher" percentage of fibres orientated in a vertical direction, compared to the surrounding dermis. At six weeks, the control, TGFβ-1 and TGFβ-2 treated wounds were visibly scarred with an abnormal accumulation of abnormally orientated collagen within the wounded area. By contrast, wounds treated with TGFβ-3 showed slightly less collagen deposition on days 7 and 14 after wounding. Moreover, the collagen deposited was in a similar reticular pattern to that of the surrounding dermis. Consequently, by six weeks after wounding, the TGFβ-3 treated wounds had a more similar dermal architecture to that of the surrounding normal skin, compared to either the control TGFβ-1 or TGFβ-2 treated wounds. . This result with TGFβ-3 is very similar to that obtained with neutralising antibodies to TGFβ-1 and TGFβ-2.
In summary, therefore, treatment of the wounds with TGFfi-3 decreased the amount of extracellular matrix deposited in the early wound, assured that the orientation of this matrix was in the normal reticular pattern of the dermis, compared to the abnormal pattern of the scar, decreased the number of macrophages and monocytes and hence inflammatory infiltrate into the wound, but greatly increased the number of blood vessels in the early healing wound. These effects are almost identical to those observed with neutralising antibodies to TGFβ-1 and TGFβ-2 except the increase in the number of blood vessels. Treatment of the wounds with neutralising antibodies to TGFβ-1 and TGFβ-2 decrease the amount of extracellular matrix deposited, alter the orientation of this matrix, so that it is in a more normal alignment, decrease the inflammatory infiltrate of macrophages and monocytes (like TGFβ-3) but decrease the number of blood vessels (unlike treatment with TGFβ-3 which increases the number of blood vessels).
TGFβ-3 therefore acts as an anti-scarring (anti-fibrotic) agent. It is very clear that this is an isoform specific effect within the TGFβ family.
TGFβ-3 therefore becomes a target as an anti-fibrotic agent or an anti-scarring agent. It may be capable of biological modification to increase the anti-fibrotic effect or define more carefully that portion of the molecule responsible for these effects. It may be possible to optimise the structure of TGFβ-3 as an anti-fibrotic agent, based on such analysis. The effects of TGFβ-3 in this regard are unpredictable from the literature, and interestingly, differ from the neutralising antibody experiments, particularly in the increase in angiogenesis. This may actually be beneficial for certain kinds of wound healing, e.g. chronic wounds such as venous leg ulcers, where one wants to increase the vascular supply to stimulate healing but decrease subsequent scarring.
In the context of fibrosis, the effects of TGFβ-3 or anti TGFβ-1/TGFβ-2 agents are not limited to preventing further increases of fibrosis. TGFβ-l/TGFβ-2 act to increase the accumulation of extracellular matrix molecules both by stimulating synthesis of new extracellular matrix molecules and decreasing the removal of existing matrix molecules, i.e. inhibiting tissue turnover (Roberts and Sporn, the transforming growth factor - β's, In: Peptide growth factors and their receptors, Springer Verlag, Berlin, 1990, p 418-472) . Therefore, any agent which antagonises or neutralises or renders ineffective TGFβ-1/TGFβ-2 not only decreases extracellular matrix synthesis but also increases remodelling. As an anti-fibrotic agent either TGFβ-3 or anti-TGFβ-1/anti- TGFβ-2/anti-PDGF (or some combination thereof) may in certain fibrotic diseases, e.g. glomerulonephritis, pulmonary fibrosis, reverse the accumulation of fibrous scar tissue already present in the tissue.
It will be appreciated that it is not intended to limit the invention to the above examples only, many variations, such as might readily occur to one skilled in the art, being possible, without departing from the scope thereof as defined in the appended claims.
Thus for example, as well as applying a preparation to a wound containing TGFβ-3 only, this may be given in combination with fibrotic growth factor neutralising agen (s), for example, anti-TGFβ-1 and/or anti-TGFβ-2 and/or anti-PDGF antibodies, in a ratio which will enable the required amount of vascularisation for the particular type of wound to be provided whilst at the same time healing the wound without scarring.

Claims

1. A healing composition containing at least one non-fibrotic growth factor in combination with a pharmaceutically acceptable carrier.
2. A composition according to claim 1, wherein the non-fibrotic growth f ctor comprises TGFβ-3.
3. A composition according to claim 1 or claim 2, wherein the non-fibrotic growth factor comprises FGF.
4. A composition according to any preceding claim,, comprising anti-fibrotic agents.
5. A composition according to claim 4, wherein the anti-fibrotic agents include antibodies to TGFβ-1, TGFβ-2 and PDGF; binding proteins which prevent TGFβ-1, TGFβ-2 and PDGF from binding to their receptors by either binding to the growth factor itself, eg. Decorin, Biglycan, or binding to the receptor, eg. peptides containing the receptor binding site sequence; or soluble forms of growth factor receptor or the growth factor binding domains of these receptors or antisense oligonucleotides or ribosymes which act to prevent fibrotic growth factor mRNA translation.
6. A composition according to any preceding claim wherein the non-fibrotic growth factor and/or anti- fibrotic agent(s) are present in the composition in an active form.
7. A composition according to any of claims 1 to 5, wherein the non-fibrotic growth factor and/or anti-fibrotic agent(s) are present in the composition in an inactive form.
8. A composition according to claim 7, wherein inactivation is by encapsulation.
9. A composition according to claim 8, wherein the capsules are degradeable by an external stimulus to release the active form when required.
10. A composition according to claim 9, wherein the external stimulus includes UV light, ultrasound, in vivo enzymes or heat.
11. A composition according to claim 7, wherein inactivation is by the molecular addition of a binding molecule which is detachable when required by an external stimulus including UV light, ultrasound, in vivo enzymes or heat.
12. A composition according to any preceding claim, wherein the non-fibrotic growth factor is present in an inactive form, for example, as a precursor, and is activated upon contact with tissue containing the natural cleavage enzymes required to convert the precursor into its active form.
13. A composition according to claim 1, wherein the carrier comprises a neutral sterile cream, gel, aerosol or powder for topical application.
14. A composition according to claim 1, wherein the carrier comprises a patch or a sterile dressing or an absorbable dressing for topically covering a wound.
15. A composition according to claim 1, wherein the carrier comprises a sterile solution for irrigation, injection or inhalation.
16. A composition according to claim 1, wherein the carrier comprises a tablet, capsule, and the like, for enteral administration.
17. A composition according to claim 1, wherein the carrier comprises a biopolymer, for example collagen, hyaluronic acid or polymer, for contacting or implanting into the wound/fibrotic lesion so as to allow release of the active agents slowly or quickly and for to be active in situ.
18. A method of preparation of a pharmaceutical healing or anti-fibrotic composition containing at least one non-fibrotic growth factor for topical application in a cream, gel, powder, aerosol, patch or dressing, biopolymer or polymer implant, delay or slow release system or in a solution for irrigation, injection or inhalation, or in a tablet or capsule for enteral administration.
19. A method of inhibiting fibrosis during the healing of wounds and other fibrotic diseases, disorders or conditions, comprising administering to a host suffering from tissue wounding or these fibrotic conditions, at least one non-fibrotic growth factor.
PCT/GB1993/000586 1992-03-28 1993-03-22 Wound healing and treatment of fibrotic disorders WO1993019769A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU37623/93A AU673161B2 (en) 1992-03-28 1993-03-22 Wound healing and treatment of fibrotic disorders
JP51719393A JP3919212B2 (en) 1992-03-28 1993-03-22 Wound healing treatment for fibrosis
DE69332624T DE69332624T2 (en) 1992-03-28 1993-03-22 Wound medication and treatment of fibrous disorders by TGFbeta-3
BR9306226A BR9306226A (en) 1992-03-28 1993-03-22 Composition of wound healing and treatment of fibrotic disorders and method for its preparation
US08/307,640 US6331298B1 (en) 1992-03-28 1993-03-22 Wound healing and treatment of fibrotic disorders
CA002131383A CA2131383C (en) 1992-03-28 1993-03-22 Wound healing and treatment of fibrotic disorders
DK93906723T DK0646012T3 (en) 1992-03-28 1993-03-22 Wound healing and treatment of fibrotic diseases by TGFbeta-3
EP93906723A EP0646012B1 (en) 1992-03-28 1993-03-22 WOUND HEALING AND TREATMENT OF FIBROTIC DISORDERS BY TGFbeta-3
AT93906723T ATE230605T1 (en) 1992-03-28 1993-03-22 WOUND HEALING AND TREATMENT OF FIBROTIC DISORDERS BY TGFBETA-3
SK1168-94A SK116894A3 (en) 1992-03-28 1993-03-22 Mixture for treatment of fibrotic disordes
NO943466A NO943466L (en) 1992-03-28 1994-09-16 Wound healing and treatment of fibrotic disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9206861.8 1992-03-28
GB929206861A GB9206861D0 (en) 1992-03-28 1992-03-28 Wound healing and treatment of fibrotic disorders

Publications (1)

Publication Number Publication Date
WO1993019769A1 true WO1993019769A1 (en) 1993-10-14

Family

ID=10713078

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/000586 WO1993019769A1 (en) 1992-03-28 1993-03-22 Wound healing and treatment of fibrotic disorders

Country Status (19)

Country Link
US (1) US6331298B1 (en)
EP (1) EP0646012B1 (en)
JP (2) JP3919212B2 (en)
AT (1) ATE230605T1 (en)
AU (1) AU673161B2 (en)
BR (1) BR9306226A (en)
CA (1) CA2131383C (en)
CZ (1) CZ236694A3 (en)
DE (1) DE69332624T2 (en)
DK (1) DK0646012T3 (en)
ES (1) ES2189790T3 (en)
GB (1) GB9206861D0 (en)
HU (1) HUT68905A (en)
NO (1) NO943466L (en)
NZ (1) NZ249937A (en)
PT (1) PT646012E (en)
RU (1) RU94042387A (en)
SK (1) SK116894A3 (en)
WO (1) WO1993019769A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449671A (en) * 1993-09-29 1995-09-12 Alcon Laboratories, Inc. Use of TGF-β3, to prevent or retard fistula closure following glaucoma filtration surgery
WO1995026203A1 (en) * 1994-03-29 1995-10-05 The Victoria University Of Manchester Wound healing
GB2288118A (en) * 1994-03-29 1995-10-11 Univ Manchester Wound healing composition
WO1996032131A1 (en) * 1993-09-29 1996-10-17 Alcon Laboratories, Inc. USE OF TGF-β3 TO REDUCE THE FORMATION OF SCAR TISSUE IN RESPONSE TO CORNEAL TRAUMA
WO1997005894A1 (en) * 1995-08-09 1997-02-20 The Victoria University Of Manchester Pharmaceutical composition containing il-10
WO1997005892A1 (en) * 1995-08-04 1997-02-20 The Victoria University Of Manchester Use of betaglycan to reduce scarring
US5621093A (en) * 1995-06-06 1997-04-15 Anika Research, Inc. Steam-sterilizing solid hyaluronic acid
WO1997015321A1 (en) * 1995-10-21 1997-05-01 The Victoria University Of Manchester Pharmaceutical composition containing an activin or inhibin stimulator
US5662904A (en) * 1991-03-28 1997-09-02 The Victoria University Of Manchester Anti-scarring compositions comprising growth factor neutralizing antibodies
US5696091A (en) * 1993-09-29 1997-12-09 Alcon Laboratories, Inc. Use of growth factor and antimetabolite combination to prevent or retard secondary cataract formation
WO2007007098A2 (en) * 2005-07-12 2007-01-18 Renovo Ltd Promotion of epithelial regeneration
US7566446B2 (en) 1996-12-04 2009-07-28 Renovo Limited Wound healing and treatment of fibrosis
US7893221B2 (en) 2006-03-11 2011-02-22 Renovo Limited Protein folding
US7902150B2 (en) 2006-03-11 2011-03-08 Renovo Limited Medicaments and proteins based on TGF-β monomers for the treatment of wounds
US7947264B2 (en) 2006-03-11 2011-05-24 Renovo Limited TGF-β3 mutants

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384634B2 (en) * 1991-08-30 2008-06-10 University Of South Florida Connective tissue growth factor
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
AU2006202209B2 (en) 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
CN101484575B (en) * 2005-06-08 2013-10-02 森托科尔公司 Cellular therapy for ocular degeneration
US20070122448A1 (en) * 2005-11-28 2007-05-31 Alireza Rezania Compositions and methods to create a vascularized environment for cellular transplantation
AU2007244675A1 (en) 2006-04-28 2007-11-08 Lifescan, Inc. Differentiation of human embryonic stem cells
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
GB0617816D0 (en) * 2006-09-11 2006-10-18 Renovo Ltd Nucleic acids and methods of protein expression
US8247384B2 (en) 2006-11-15 2012-08-21 Coda Therapeutics, Inc. Methods and compositions for wound healing
EP2126045A4 (en) * 2007-01-30 2010-05-26 Univ Georgia Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (mmc)
US9080145B2 (en) * 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
BRPI0813787A2 (en) 2007-07-01 2014-10-07 Lifescan Inc ISOLATED PLURIPOTENT STEM CELL CULTURE
AU2008273813B2 (en) * 2007-07-12 2013-06-13 Compugen Ltd. Bioactive peptides and method of using same
CA2693156C (en) 2007-07-18 2018-03-06 Alireza Rezania Differentiation of human embryonic stem cells
RU2473685C2 (en) 2007-07-31 2013-01-27 Лайфскен, Инк. Differentiation of human embryo stem cells
ATE523585T1 (en) * 2007-11-27 2011-09-15 Lifescan Inc DIFFERENTIATION OF HUMAN EMBRYONAL STEM CELLS
CA2710388A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides for the treatment of abnormal or excessive scars
CA2710386A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Improved medical devices
US20110217313A1 (en) * 2007-12-21 2011-09-08 Becker David L Treatment of orthopedic conditions
KR20190057164A (en) 2008-02-21 2019-05-27 얀센 바이오테크 인코포레이티드 Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
JP5734183B2 (en) * 2008-06-30 2015-06-17 ヤンセン バイオテツク，インコーポレーテツド Differentiation of pluripotent stem cells
CA2728930C (en) 2008-07-07 2014-12-09 Laboratoire Medidom S.A. Temperature reducing, healing wound dressing
US20110305672A1 (en) 2008-07-25 2011-12-15 University Of Georgia Research Foundation, Inc. COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
CN102165058B (en) 2008-07-25 2015-07-01 佐治亚大学研究基金会 Compositions for mesoderm derived ISLl1+ multipotent cells (IMPs), epicardial progenitor cells (EPCs) and multipotent CXCR4+CD56+ cells (C56Cs) and methods of use
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
RU2528861C2 (en) * 2008-10-31 2014-09-20 Сентокор Орто Байотек Инк. Differentiation of human embryonic stem cell into pancreatic endocrine cell line
CN102272291B (en) 2008-10-31 2018-01-16 詹森生物科技公司 Differentiation of the human embryo stem cell to pancreatic endocrine pedigree
BRPI0920956A2 (en) 2008-11-20 2015-08-18 Centocor Ortho Biotech Inc Pluripotent stem cell culture in microvessels
RU2547925C2 (en) * 2008-11-20 2015-04-10 Сентокор Орто Байотек Инк. Methods and compositions for cell fixation and culture on flat carriers
GB2485112B (en) * 2009-07-20 2014-02-26 Janssen Biotech Inc Differentiation of human embryonic stem cells
SG177416A1 (en) 2009-07-20 2012-02-28 Janssen Biotech Inc Differentiation of human embryonic stem cells
WO2011011300A2 (en) 2009-07-20 2011-01-27 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells
AR078805A1 (en) * 2009-10-29 2011-12-07 Centocor Ortho Biotech Inc PLURIPOTENT MOTHER CELLS
DE202009017772U1 (en) * 2009-12-10 2011-04-21 Orthogen Ag Combination preparations with cytokine antagonist and corticosteroid
RU2701335C2 (en) 2009-12-23 2019-09-25 Янссен Байотек, Инк. Method for producing population of pancreatic endocrine cells co-expressing nkx6.1 and insulin, and method of treating diabetes
ES2633648T3 (en) 2009-12-23 2017-09-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
CA2791476C (en) 2010-03-01 2020-06-30 Janssen Biotech, Inc. Methods for purifying cells derived from pluripotent stem cells
RU2663339C1 (en) 2010-05-12 2018-08-03 Янссен Байотек, Инк. Differentiation of human embryo stem cells
WO2012021698A2 (en) 2010-08-12 2012-02-16 Janssen Biotech, Inc. Treatment of diabetes with pancreatic endocrine precursor cells
CN103221536B (en) 2010-08-31 2016-08-31 詹森生物科技公司 The differentiation of human embryo stem cell
PL2611910T3 (en) 2010-08-31 2018-06-29 Janssen Biotech, Inc Differentiation of human embryonic stem cells
EP2611907B1 (en) 2010-08-31 2016-05-04 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US9404087B2 (en) 2010-12-15 2016-08-02 Kadimastem Ltd. Insulin producing cells derived from pluripotent stem cells
EP2794857A4 (en) 2011-12-22 2015-07-08 Janssen Biotech Inc Differentiation of human embryonic stem cells into single hormonal insulin positive cells
CA2866590A1 (en) 2012-03-07 2013-09-12 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
EP3450542B1 (en) 2012-06-08 2021-09-01 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
CA2896658C (en) 2012-12-31 2021-06-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators
RU2658488C2 (en) 2012-12-31 2018-06-21 Янссен Байотек, Инк. Method for obtaining cells expressing markers characteristic for pancreatic endocrine cells
WO2014106141A1 (en) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
EP2972193B1 (en) 2013-03-13 2019-12-18 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
KR102162138B1 (en) 2014-05-16 2020-10-06 얀센 바이오테크 인코포레이티드 Use of small molecules to enhance mafa expression in pancreatic endocrine cells
CN114010788A (en) 2014-08-22 2022-02-08 奥克兰联合服务有限公司 Channel modulators
WO2017094001A1 (en) 2015-11-30 2017-06-08 Kadimastem Ltd Methods for differentiating and purifying pancreatic endocrine cells
RU2018131123A (en) 2016-02-17 2020-03-17 Новартис Аг ANTIBODIES TO TGF-BETA2
MA45479A (en) 2016-04-14 2019-02-20 Janssen Biotech Inc DIFFERENTIATION OF PLURIPOTENT STEM CELLS IN ENDODERMAL CELLS OF MIDDLE INTESTINE
JP7531887B2 (en) 2020-07-31 2024-08-13 学校法人関西医科大学 Tissue fibrosis inhibitor containing TGF-β
IL300393A (en) 2020-08-21 2023-04-01 Univ Miami Compositions and methods of treatment using microvesicles from bone marrow-derived mesenchymal stem cells
WO2023205158A1 (en) 2022-04-19 2023-10-26 University Of Miami Compositions comprising microvesicles for use in the prevention and treatment of graft versus host disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990003810A1 (en) * 1988-10-07 1990-04-19 Ed Geistlich Söhne Ag Für Chemische Industrie Delayed release compositions for wound healing
EP0375127A1 (en) * 1988-11-02 1990-06-27 Genentech, Inc. Composition for the treatment of periodontal disease
EP0433225A1 (en) * 1989-12-06 1991-06-19 Ciba-Geigy Ag Process for the production of biologically active protein (e.g. TGF)
WO1991010727A1 (en) * 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
WO1992017206A1 (en) * 1991-03-28 1992-10-15 The Victoria University Of Manchester Wound healing

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155214A (en) * 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990003810A1 (en) * 1988-10-07 1990-04-19 Ed Geistlich Söhne Ag Für Chemische Industrie Delayed release compositions for wound healing
EP0375127A1 (en) * 1988-11-02 1990-06-27 Genentech, Inc. Composition for the treatment of periodontal disease
EP0433225A1 (en) * 1989-12-06 1991-06-19 Ciba-Geigy Ag Process for the production of biologically active protein (e.g. TGF)
WO1991010727A1 (en) * 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
WO1992017206A1 (en) * 1991-03-28 1992-10-15 The Victoria University Of Manchester Wound healing

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662904A (en) * 1991-03-28 1997-09-02 The Victoria University Of Manchester Anti-scarring compositions comprising growth factor neutralizing antibodies
US5696091A (en) * 1993-09-29 1997-12-09 Alcon Laboratories, Inc. Use of growth factor and antimetabolite combination to prevent or retard secondary cataract formation
WO1996032131A1 (en) * 1993-09-29 1996-10-17 Alcon Laboratories, Inc. USE OF TGF-β3 TO REDUCE THE FORMATION OF SCAR TISSUE IN RESPONSE TO CORNEAL TRAUMA
US5449671A (en) * 1993-09-29 1995-09-12 Alcon Laboratories, Inc. Use of TGF-β3, to prevent or retard fistula closure following glaucoma filtration surgery
WO1995026203A1 (en) * 1994-03-29 1995-10-05 The Victoria University Of Manchester Wound healing
GB2288118A (en) * 1994-03-29 1995-10-11 Univ Manchester Wound healing composition
EP0968723A1 (en) * 1994-03-29 2000-01-05 The Victoria University Of Manchester Healing of wounds or fibrotic disorders using at least one agent against a growth factor
US5972335A (en) * 1994-03-29 1999-10-26 The Victoria University Of Manchester Wound healing
AU710153B2 (en) * 1994-03-29 1999-09-16 Renovo Limited Wound healing
US5621093A (en) * 1995-06-06 1997-04-15 Anika Research, Inc. Steam-sterilizing solid hyaluronic acid
WO1997005892A1 (en) * 1995-08-04 1997-02-20 The Victoria University Of Manchester Use of betaglycan to reduce scarring
US6060460A (en) * 1995-08-04 2000-05-09 The Victoria University Of Manchester Use of betaglycan to reduce scarring
US7052684B2 (en) 1995-08-09 2006-05-30 Renovo Limited Methods of healing wounds and fibrotic disorders using IL-10
WO1997005894A1 (en) * 1995-08-09 1997-02-20 The Victoria University Of Manchester Pharmaceutical composition containing il-10
US6387364B1 (en) 1995-08-09 2002-05-14 Renovo Limited Methods of healing wounds and fibrotic disorders using IL-10
US7713933B2 (en) 1995-10-21 2010-05-11 Renovo Limited Pharmaceutical composition containing an activin or inhibin stimulator
WO1997015321A1 (en) * 1995-10-21 1997-05-01 The Victoria University Of Manchester Pharmaceutical composition containing an activin or inhibin stimulator
US7566446B2 (en) 1996-12-04 2009-07-28 Renovo Limited Wound healing and treatment of fibrosis
WO2007007098A2 (en) * 2005-07-12 2007-01-18 Renovo Ltd Promotion of epithelial regeneration
WO2007007098A3 (en) * 2005-07-12 2007-05-18 Renovo Ltd Promotion of epithelial regeneration
EP2298336A3 (en) * 2005-07-12 2011-07-13 Renovo Limited Promotion of epithelial regeneration
US7893221B2 (en) 2006-03-11 2011-02-22 Renovo Limited Protein folding
US7902150B2 (en) 2006-03-11 2011-03-08 Renovo Limited Medicaments and proteins based on TGF-β monomers for the treatment of wounds
US7947264B2 (en) 2006-03-11 2011-05-24 Renovo Limited TGF-β3 mutants

Also Published As

Publication number Publication date
PT646012E (en) 2003-03-31
EP0646012A1 (en) 1995-04-05
DE69332624T2 (en) 2003-10-02
US6331298B1 (en) 2001-12-18
EP0646012B1 (en) 2003-01-08
BR9306226A (en) 1996-12-03
NO943466D0 (en) 1994-09-16
HUT68905A (en) 1995-08-28
DK0646012T3 (en) 2003-03-03
ES2189790T3 (en) 2003-07-16
NZ249937A (en) 1996-09-25
ATE230605T1 (en) 2003-01-15
JP2005290009A (en) 2005-10-20
JPH07505378A (en) 1995-06-15
AU673161B2 (en) 1996-10-31
CZ236694A3 (en) 1995-04-12
RU94042387A (en) 1996-11-10
NO943466L (en) 1994-09-16
DE69332624D1 (en) 2003-02-13
CA2131383C (en) 2002-07-16
GB9206861D0 (en) 1992-05-13
CA2131383A1 (en) 1993-10-14
JP3919212B2 (en) 2007-05-23
HU9402771D0 (en) 1995-01-30
SK116894A3 (en) 1995-02-08
AU3762393A (en) 1993-11-08

Similar Documents

Publication Publication Date Title
EP0646012B1 (en) WOUND HEALING AND TREATMENT OF FIBROTIC DISORDERS BY TGFbeta-3
Yang et al. Modulation of macrophages by a paeoniflorin-loaded hyaluronic acid-based hydrogel promotes diabetic wound healing
Schultz et al. EGF and TGF‐α in wound healing and repair
JP3930556B2 (en) Use of mannose phosphates in the treatment of fibrotic diseases
JP4083794B2 (en) Wound healing
WO1992017206A1 (en) Wound healing
JP4307561B2 (en) Wound healing
CN114712385A (en) New application of dextran sulfate
WO2013059879A1 (en) Compositions and methods for the treatment of fibrosis and fibrotic diseases
EP0941108B1 (en) Wound healing and treatment of fibrosis
EP0855916B1 (en) Pharmaceutical composition containing an activin stimulator
US11890322B2 (en) Methods for promoting wound healing and hair growth comprising GDNF administration
CN110170046A (en) Application of the fibroblast growth factor 21 in preparation treatment acute pancreatitis drug
US6060460A (en) Use of betaglycan to reduce scarring
JP5860406B2 (en) Sustained release pharmaceutical composition
Schweigerer Basic fibroblast growth factor: properties and clinical implications
US20090022802A1 (en) Cardiomyopathy therapeutic agent
KR100249136B1 (en) Use of mannose phosphates for the treatment of fibrotic disorders
US20050025743A1 (en) Method of preventing adhesions wtih ifn-upsilon
JPH06157340A (en) Medicine for trauma
JP2003246752A (en) Therapeutic agent for cardiomyopathy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1993906723

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2131383

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 249937

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 08307640

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 116894

Country of ref document: SK

Ref document number: PV1994-2366

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1993906723

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1994-2366

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV1994-2366

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1993906723

Country of ref document: EP